Post Profile

Biotech company Alnylam Pharmaceuticals is down almost 50% Thursday after stopping a late-stage clinical trial.
The drug, revusiran, was being developed to treat a condition called hereditary ATTR amyloidosis with cardiomyopathy. It's a rare disease in which amyloid proteins build up in the body, in particular the heart.
Alnylam discontinued the trial after 18 patients died who were part of the trial.read more

share

Related Posts

Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts. Even the Nasdaq Biotechnology Index can swing wildl...

According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year. This growth is due to rising research and development of new drugs, along with well-established pro...

Shares of Eleven Biotherapeutics fell to nearly zero on Monday after the company announced failed test results on a key drug.
In a statement Monday, the company said its lead drug candidate failed a Phase 3 study to treat moderate t...

In 2013, a number of new drugs got approvals from the FDA. This provided a boost to the biotech industry as a whole. Now, this speculative growth market is so sensitive that even positive results from clinical trials can take a comp...

Shares of biotech Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have soared over 160% in the past year. The company’s a leader in developing drugs and delivery systems centered on RNA interference, or RNAi, It’s an emerging area that ...